MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202511133421 A) filed by Manjusha Dhande Borde; Ipseeta Ray Mohanty; Rajesh Kumar Suman; and Shalini Vijay Rakhade, Navi Mumbai, Maharashtra, on Dec. 30, 2025, for 'a cardioprotective pharmaceutical composition comprising terminalia arjuna and metformin acting through dpp-4 inhibition for the management of diabetes-associated myocardial infarction.'
Inventor(s) include Manjusha Dhande Borde; Ipseeta Ray Mohanty; Rajesh Kumar Suman; and Shalini Vijay Rakhade.
The application for the patent was published on Jan. 9, under issue no. 02/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a cardioprotective pharmaceutical composition and method for the management of myocardial infarction co-existing with diabetes mellitus. The invention discloses a synergistic combination of Terminalia arjuna extract and metformin, wherein Terminalia arjuna functions as a natural dipeptidyl peptidase-4 (DPP-4) inhibitor to enhance glycemic control and provide myocardial protection. The combination therapy modulates key pathological biomarkers including DPP-4, creatine phosphokinase-MB (CPK-MB), high-sensitivity C-reactive protein (hs-CRP), lipid parameters, and apoptotic signaling pathways, thereby reducing myocardial injury, inflammation, oxidative stress, and cardiomyocyte apoptosis. Experimental evaluation in a model of diabetes-associated myocardial infarction demonstrates that the disclosed composition provides cardioprotective efficacy comparable to synthetic DPP-4 inhibitor-based therapies while maintaining organ safety and improved tolerability, offering a safe, cost-effective, and multifunctional therapeutic approach for managing cardiovascular complications in diabetes mellitus."
Disclaimer: Curated by HT Syndication.
